The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04129216

Recruitment Status : Recruiting

First Posted : October 16, 2019

Last Update Posted : December 1, 2021

See Contacts and Locations

Sponsor:

Collaborator:

Agendia

Information provided by (Responsible Party):

Johns Hopkins University

Study Description

Brief Summary:

The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: Tamoxifen Citrate Drug: Letrozole Drug: Exemestane Diagnostic Test: Blueprint Diagnostic Test: Mammaprint	Phase 2

Detailed Description:

Breast cancer is among the most common malignancies in women in the United States. Over the years breast cancer management have dramatically developed from the extensive surgical approach toward the breast conservative approach. This was mainly due to the introduction of chemotherapy and hormonal therapy. Hormonal therapy in particular has been shown to improve the oncological outcomes of the breast cancer. However, while this is well documented in the clinical outcomes. Little is known in regards what happens on the genetic level. As such in this study the investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.

The hypothesis of this study is that short-term, preoperative hormonal treatment will induce genetic changes associated with reduced proliferation, including lower Ki67 expression, and changes in Estrogen Receptor (ER) and Progesterone Receptor (PR) expression. The data from such investigation will be very helpful in advancing the individualized care to women with breast cancer.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	30 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Patients will start the hormone therapy before surgery; the investigators look for the genomic profiles of the tumor before and after chemotherapy
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Actual Study Start Date :	February 20, 2019
Estimated Primary Completion Date :	November 26, 2022
Estimated Study Completion Date :	November 26, 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Breast cancer

MedlinePlus related topics: Breast Cancer Genes and Gene Therapy

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Tamoxifen arm for premenopausal patients	Drug: Tamoxifen Citrate 10mg administered daily. Patients take this drug for 2-6 weeks Other Name: Soltamox Diagnostic Test: Blueprint studies the genomics of the tumor and tumor behavior Diagnostic Test: Mammaprint studies the genomics of the tumor
Experimental: Letrozole arm for postmenopausal patients	Drug: Letrozole 2.5mg is administered daily. Patients take this drug for 2-6 weeks Other Name: Femara Diagnostic Test: Blueprint studies the genomics of the tumor and tumor behavior Diagnostic Test: Mammaprint studies the genomics of the tumor
Experimental: Exemestane arm for postmenopausal patients	Drug: Exemestane 25mg is administered daily. Patients take this drug for 2-6 weeks. Other Name: Aromasin Diagnostic Test: Blueprint studies the genomics of the tumor and tumor behavior Diagnostic Test: Mammaprint studies the genomics of the tumor

Outcome Measures

Primary Outcome Measures :

Change in percent expression of Ki67 measured by immunohistochemistry (IHC) [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
This is a measure of tumor proliferation, and will be determined at baseline and at time of surgery.
Change in percent expression of Ki67 measured by single-gene read out [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
This is a measure of tumor proliferation, and will be determined at baseline and at time of surgery.

Secondary Outcome Measures :

Change in the Mammaprint risk report [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
Mammaprint risk score is binary (high risk of recurrence or low risk of recurrence).
Change in percent ER expression as measured by IHC [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
Units for Estrogen Receptor protein expression are percent based. >10 percent is positive, <1 percent is negative. 1-10 percent is weakly positive or focally positive.
Change in percent ER expression as measured by single-gene read out [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
Units for Estrogen Receptor protein expression are percent based. >10 percent is positive, <1 percent is negative. 1-10 percent is weakly positive or focally positive.
Change in percent PR expression as measured by IHC [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
Units for Progesterone Receptor protein expression are percent based. >10 percent is positive, <1 percent is negative. 1-10 percent is weakly positive or focally positive.
Change in percent PR expression as measured by single-gene read out [ Time Frame: Baseline and at Time of surgery, up to 6 weeks ]
Units for Progesterone Receptor protein expression are percent based. >10 percent is positive, <1 percent is negative. 1-10 percent is weakly positive or focally positive.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria

Treatment-naïve, histologically confirmed invasive ductal breast cancer between stages 1 to 3.
Co-enrollment in the FLEX Registry
Estrogen Receptor Positive (ER+) Progesterone Receptor Positive (PR+) confirmed hormone receptor status measured by immunohistochemistry (IHC)
Patients should understand patients' condition and be able to give informed consent to participate

Exclusion criteria

History of hormonal therapy, chemotherapy, radiation therapy, or novel therapy to treat the current breast cancer.
Allergic reactions/hypersensitivity to tamoxifen, letrozole, or exemestane or any of the ingredients of these drugs.
Any contraindication to hormonal therapy, such as history of thromboembolic disease or uterine cancer.
Patients without invasive disease (stage 0)
Patients with metastatic breast cancer(stageIV)
Patients that are Human Epidermal Growth Factor 2+(HER2+) by IHC/Fluorescence in situ hybridization (FISH).

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04129216

Contacts

Layout table for location contacts

Contact: Mehran Habibi, MD	4105501226	mhabibi2@jhmi.edu

Locations

Layout table for location information

United States, Maryland
Johns Hopkins Bayview Hospital	Recruiting
Baltimore, Maryland, United States, 21224
Contact: Mehran Habibi, MD 410-550-1226 mhabibi2@jhmi.edu

Sponsors and Collaborators

Johns Hopkins University

Agendia

Investigators

Layout table for investigator information

Principal Investigator:	Mehran Habibi, MD	Johns Hopkins Bayview

More Information

Layout table for additonal information

Responsible Party:	Johns Hopkins University
ClinicalTrials.gov Identifier:	NCT04129216
Other Study ID Numbers:	IRB00130428
First Posted:	October 16, 2019 Key Record Dates
Last Update Posted:	December 1, 2021
Last Verified:	November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	Yes
Product Manufactured in and Exported from the U.S.:	No

Keywords provided by Johns Hopkins University:


breast cancer genomic assay hormone therapy

Additional relevant MeSH terms:

Layout table for MeSH terms

Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Tamoxifen Letrozole Exemestane Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Aromatase Inhibitors	Steroid Synthesis Inhibitors Enzyme Inhibitors Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Selective Estrogen Receptor Modulators Estrogen Receptor Modulators Bone Density Conservation Agents

To Top